Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Geophysical Research Letters|July 28, 2020
Hagen Bræ: A Surging Glacier in North Greenland-35 Years of ObservationsA M Solgaard, S B Simonsen, A Grinsted, et al.
Environmental Pollution (Barking, Essex : 1987)|November 17, 2023
Evaluation of precopulatory pairing behaviour and male fertility in a marine amphipod exposed to plastic additivesBidemi Green-Ojo, Marina Tenório Botelho, Gisela de Aragão Umbuzeiro, et al.
Physical and Engineering Sciences in Medicine|July 15, 2020
Technique, radiation safety and image quality for chest X-ray imaging through glass and in mobile settings during the COVID-19 pandemicZoe Brady, Heather Scoullar, Ben Grinsted, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2015
Atlantic hurricane surge response to geoengineeringJohn C Moore, Aslak Grinsted, Xiaoran Guo, et al.
Journal of Crohn'S & Colitis|November 30, 2020
Systematic Review of Factors Affecting Transition Readiness Skills in Patients with Inflammatory Bowel DiseaseLara E Johnson, Matthew J Lee, Rhys Turner-Moore, et al.
Nature Communications|September 23, 2022
Accelerating ice flow at the onset of the Northeast Greenland Ice StreamAslak Grinsted, Christine S Hvidberg, David A Lilien, et al.
British Journal of Cancer|September 1, 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphomaA Naing, C Aghajanian, E Raymond, et al.
Cancer Chemotherapy and Pharmacology|September 29, 2011
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumorsSuzanne Leijen, Patricia M M B Soetekouw, T R Jeffry Evans, et al.
British Journal of Clinical Pharmacology|November 10, 2025
A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinomaShankar Lanke, Kowser Miah, Damilola Olabode, et al.
The Lancet. Oncology|December 4, 2012
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyPasi A Jänne, Alice T Shaw, José Rodrigues Pereira, et al.
Pageof 15